Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future

被引:1102
作者
Muller, RH [1 ]
Jacobs, C [1 ]
Kayser, O [1 ]
机构
[1] Free Univ Berlin, Inst Pharm Pharmzeut Technol Biopharm & Biotechno, D-12169 Berlin, Germany
关键词
nanosuspension; homogenisation; drug targeting; drug delivery; parasitic infection; Leishmania; poor solubility;
D O I
10.1016/S0169-409X(00)00118-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An increasing number of newly developed drugs are poorly soluble: in many cases drugs are poorly soluble in both aqueous and organic media excluding the traditional approaches of overcoming such solubility factors and resulting in bioavailability problems. An alternative and promising approach is the production of drug nanoparticles (i.e. nanosuspensions) to overcome these problems. The major advantages of this technology are its general applicability to most drugs and its simplicity. In this article, the production of nanoparticles on a laboratory scale is presented, special features such as increased saturation solubility and dissolution velocity are discussed, and special applications are highlighted, for example, mucoadhesive nanosuspensions for oral delivery and surface-modified drug nanoparticles for sire-specific delivery to the brain. The possibilities of large scale production - the prerequisite for the introduction of a delivery system to the market are also discussed. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:3 / 19
页数:17
相关论文
共 52 条
[1]  
[Anonymous], EMULSIONS NANOSUSPEN, DOI DOI 10.1002/jps.10590
[2]  
BERNOULLI P, 1978, PHARM TECHNOLOGIE GE, P101
[3]  
Blunk T, 1996, EUR J PHARM BIOPHARM, V42, P262
[4]   COLLOIDAL CARRIERS FOR INTRAVENOUS DRUG TARGETING - PLASMA-PROTEIN ADSORPTION PATTERNS ON SURFACE-MODIFIED LATEX-PARTICLES EVALUATED BY 2-DIMENSIONAL POLYACRYLAMIDE-GEL ELECTROPHORESIS [J].
BLUNK, T ;
HOCHSTRASSER, DF ;
SANCHEZ, JC ;
MULLER, BW ;
MULLER, RH .
ELECTROPHORESIS, 1993, 14 (12) :1382-1387
[5]  
BLUNK T, 1993, PHARM IND, V55, P612
[6]  
Blunk T., 1994, THESIS CHRISTIAN ALB
[7]  
BOHM BHL, 1999, THESIS FREIE U BERLI
[8]  
BUCHMANN S, 1996, P 42 ANN C APV MAINZ, P124
[9]   Bioadhesion of solid oral dosage forms, why and how? [J].
Duchene, D ;
Ponchel, G .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1997, 44 (01) :15-23
[10]  
GASSMANN P, 1994, EUR J PHARM BIOPHARM, V40, P64